Failure to Follow Trial Plans Lands Investigators FDA Warnings

Clinical Trials Advisor
A Georgia clinical investigator was warned by the FDA for failing to properly randomize and dose patients participating in a GlaxoSmithKline study evaluating albiglutide in patients with type 2 diabetes.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00